- Home
- PK vs RCUS Comparison
PK vs RCUS Comparison
Compare PK & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PK
- RCUS
- Stock Information
- Founded
- PK 1946
- RCUS 2015
- Country
- PK United States
- RCUS United States
- Employees
- PK N/A
- RCUS N/A
- Industry
- PK Real Estate Investment Trusts
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- PK Real Estate
- RCUS Health Care
- Exchange
- PK Nasdaq
- RCUS Nasdaq
- Market Cap
- PK 2.0B
- RCUS 2.4B
- IPO Year
- PK N/A
- RCUS 2018
- Fundamental
- Price
- PK $10.11
- RCUS $19.94
- Analyst Decision
- PK Hold
- RCUS Buy
- Analyst Count
- PK 10
- RCUS 8
- Target Price
- PK $11.50
- RCUS $27.63
- AVG Volume (30 Days)
- PK 3.7M
- RCUS 1.8M
- Earning Date
- PK 10-30-2025
- RCUS 10-28-2025
- Dividend Yield
- PK 9.86%
- RCUS N/A
- EPS Growth
- PK N/A
- RCUS N/A
- EPS
- PK N/A
- RCUS N/A
- Revenue
- PK $2,541,000,000.00
- RCUS $240,000,000.00
- Revenue This Year
- PK $0.42
- RCUS N/A
- Revenue Next Year
- PK $2.10
- RCUS N/A
- P/E Ratio
- PK N/A
- RCUS N/A
- Revenue Growth
- PK N/A
- RCUS N/A
- 52 Week Low
- PK $8.27
- RCUS $6.50
- 52 Week High
- PK $16.23
- RCUS $22.11
- Technical
- Relative Strength Index (RSI)
- PK 38.29
- RCUS 64.34
- Support Level
- PK $10.60
- RCUS $19.33
- Resistance Level
- PK $10.94
- RCUS $20.99
- Average True Range (ATR)
- PK 0.35
- RCUS 1.17
- MACD
- PK -0.00
- RCUS -0.19
- Stochastic Oscillator
- PK 19.55
- RCUS 43.93
About PK Park Hotels & Resorts Inc.
Park Hotels & Resorts owns upper-upscale and luxury hotels, with 22,395 rooms across 36 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of Hilton Worldwide Holdings at the start of 2017, so most of its hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.